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Abstract
Hepatitis B virus genotype D can be found in many parts of the world and is the most prevalent strain in south-eastern
Europe, the Mediterranean Basin, the Middle East, and the Indian sub-continent. The epidemiological history of the D
genotype and its subgenotypes is still obscure because of the scarcity of appropriate studies. We retrieved from public
databases a total of 312 gene P sequences of HBV genotype D isolated in various countries throughout the world, and
reconstructed the spatio-temporal evolutionary dynamics of the HBV-D epidemic using a Bayesian framework. The
phylogeographical analysis showed that India had the highest posterior probability of being the location of the tree root,
whereas central Asia was the most probable location of the common ancestor of subgenotypes D1–D3. HBV-D5 (identified
in native Indian populations) diverged from the tree root earlier than D1–D3. The time of the most recent common ancestor
(tMRCA) of the tree root was 128 years ago, which suggests that the common ancestor of the currently circulating
subgenotypes existed in the second half of the XIX century. The mean tMRCA of subgenotypes D1–D3 was between the
1940s and the 1950–60s. On the basis of our phylogeographic reconstruction, it seems that HBV-D reached the
Mediterranean area in the middle of the XX century by means of at least two routes: the first pathway (mainly due to the
spread of subgenotype D1) crossing the Middle East and reaching north Africa and the eastern Mediterranean, and the
second pathway (closely associated with D2) that crossed the former Soviet Union and reached eastern Europe and the
Mediterranean through Albania. We hypothesise that the main route of dispersion of genotype D was the unsafe use of
injections and drug addiction.
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Introduction
Hepatitis B virus (HBV) is an enveloped DNA virus belonging to
the Hepadnaviridae family: its genome is a small, circular partially
double-stranded DNA molecule of about 3.7 kilobases including
four open reading frames (S, C, P and X) coding for seven proteins
(three surface proteins, two core antigens, the polymerase and the
X protein).
HBV is the leading cause of liver disease and infects an
estimated 240 million people worldwide [1]. Despite the recent
decrease in the rate of new cases, about 7–8,000 new diagnoses are
made every year in Europe [2]. The prevalence of HBV infection
in Europe varies widely: in general, it is higher in south-eastern
than north-western countries [2]. The highest prevalence rates are
in Turkey, Romania, Bulgaria, Greece, Albania and southern Italy
[3,4].
HBV is characterised by a high degree of genetic heterogeneity
due to the use of a reverse transcriptase during viral replication.
Eight main genotypes (A–H) that differ genetically by at least 8%
have so far been identified [5], some of which further segregate
into subgenotypes with a mean genetic distance of about 4% [6].
The genotypes and subgenotypes have a distinct ethno-geo-
graphical distribution. The ubiquitous genotypes A and D are
respectively the most prevalent in north-western and south-eastern
Europe/Mediterranean countries [5]. Seven main HBV-D sub-
genotypes have so far been described (D1–D7). Considering only
Europe and the Mediterranean area, D1 is the most prevalent
subgenotype in Greece, Turkey, and north Africa [7–10], D2 the
most prevalent in north-eastern Europe (Russia, Belarus, Estonia)
and Albania [11,12], and D3 the most prevalent in Italy and
Serbia [13–15]. Some specific D strains are restricted to more
limited geographical areas: D7 in Tunisia and Morocco [16,17],
D6 in Papua and Indonesia [18], and D5 in India, where all of the
main D subgenotypes are also found [19]. Finally, D4 is the
dominant subgenotype in Oceania [20].
The epidemiological history of the HBV-D genotype is still
unclear because of the scarcity of appropriate studies. The aim of
this study was to use a recently developed Bayesian approach to
virus phylogeography analysis [21] in order to reconstruct the
spatial and temporal dynamics of HBV-D genotype, with
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particular reference to the origin and the geographic dispersion of
the principal D subgenotypes circulating in south-eastern Europe,
the Middle East and the Mediterranean basin.
Methods
HBV genotype D data set
We retrieved from public databases (Genbank at http://www.
ncbi.nlm.nih.gov/genbank/) a total of 312 P gene sequences of
HBV-D isolated in various countries of the world, with particular
attention being given to eastern Europe, the eastern Mediterra-
nean and the Middle East (including 63 Italian and 59 Albanian
isolates previously characterised by us) [12,22]. The viral
sequences were selected on the basis of the following inclusion
criteria: 1) they had been published in peer-reviewed journals; 2)
there was no uncertainty about the sub-type assignment of each
sequence and all were classified as non-recombinant; and 3) the
city/state of origin were known and clearly stated in the original
publication. The sequences were aligned using ClustalX software
[23] and cropped to the same length of 990 nucleotides coding for
a region of the P protein between amino acids 305 and 634, and
the overlapping S, PreS2 and PreS1 regions [13]. They were
manually edited using Bioedit software (Tom Hall, 2011; available
at http://www.mbio.ncsu.edu/bioedit/bioedit.html). The sam-
pling locations were Albania (n = 59), central Asia (n = 10),
Egypt/Israel (n = 5), the Far East (n = 8), Greece (n = 4), India
(n = 26), Iran (n = 13), Italy (n = 63), Russia (n = 53), Serbia (n = 3),
South Africa (n = 6), Spain (n = 4), Tunisia (n = 41), and Turkey
(n = 17).
Likelihood mapping analysis
In order to obtain an overall impression of the phylogenetic
signals in the HBV P sequences, we used likelihood mapping to
analse 10,000 random quartets generated using TreePuzzle
[24,25]. A likelihood map consists of an equilateral triangle
containing dots representing the likelihoods of the three possible
unrooted trees for a set of four sequences (quartets) randomly
selected from the data set: the dots near the corners or sides
respectively represent tree-like (fully resolved phylogenies in which
one tree is clearly better than the others) or network-like
phylogenetic signals (three regions in which it is not possible to
decide between two topologies). The central area of the map
represents a star-like signal (the region in which the star tree is
optimal).
Estimated evolutionary rates and time-scaled phylogeny
reconstruction
To estimate the evolutionary rates of the HBV P gene
sequences, we used molecular clock models based on the isolation
dates of the tips of a tree. As sampling dates were not available for
all of the sequences included in the analysis, we used an external
calibration approach previously adopted by other authors [26,27].
The evolutionary rates were estimated on a smaller data set
including only isolates for which the sampling years were known.
The estimated mean evolutionary rate was used to define a priors
probability distribution during the analysis of the main data set.
The smaller data-set included 216 isolates from the same places as
those of the main data set and the sampling dates ranged from
1980 to 2007. The evolutionary model that best fitted the data was
selected using an information criterion implemented in JModelT-
est [28], which is freely available at http://darwin.uvigo.es/
software/jmodeltest.html.
The evolutionary rates were estimated using a Bayesian Markov
Chain Monte Carlo (MCMC) method implemented in BEAST
1.5.4 [29] under a strict and relaxed molecular clock, and an
uncorrelated log normal rate distribution model. As coalescent
priors, we compared three simple parametric demographic models
of population growth (constant size, and exponential and logistic
growth) and a piecewise-constant model, called Bayesian skyline
plot (BSP). The same Bayesian MCMC method, with the same
substitution, molecular clock and demographic models were used
to reconstruct the time-scaled phylogeny of the main data set, and
statistical support for specific clades was obtained by calculating
the posterior probability of each monophyletic clade.
The MCMC chains were run for at least 50 million generations,
and sampled every 5000 steps. Convergence was assessed on the
basis of the effective sampling size (ESS) after a 10% burn-in using
Tracer software version 1.5 ( http://tree.bio.ed.ac.uk/software/
tracer/ ). Only ESS’s of .250 were accepted. Uncertainty in the
estimates was indicated by 95% highest posterior density (95%
HPD) intervals, and the best fitting models were selected by means
of a Bayes factor (BF, using marginal likelihoods) implemented in
BEAST [30]. In accordance with Kass and Raftery [31], the
strength of the evidence against H0 was evaluated as
2lnBF,2= no evidence; 2–6 weak evidence; 6–10 strong evi-
dence; and .10 very strong evidence. A negative 2LnBF indicated
evidence in favour of H0. Only values of $10 were considered
significant.
Bayesian phylogeography
The spatial reconstruction was obtained by means of the same
Bayesian framework using a continuous time Markov Chain
(CTMC) implemented in BEAST [21] over discrete sampling
locations. The Bayesian Stochastic Search Variable Selection
(BSSVS) model was implemented, which allows the diffusion rates
to be zero with a positive prior probability. Comparison of the
posterior and prior probabilities of individual rates being zero
provided a formal BF to test the significance of the linkages
between locations. Rates yielding a BF of .6 were considered well
supported and formed the migration pathway. The maximum
clade credibility (MCC) tree (i.e. the tree with the largest product
of posterior clade probabilities) was selected from the posterior tree
distribution using the program TreeAnnotator (included in the
Beast package) after a 10% burn in. The final trees were
manipulated in FigTree v.1.3 for display purposes. The significant
migration rates were analysed and visualised by SPREAD [32]
a recently developed application available at http://www.
kuleuven.be/aidslab/phylogeography/SPREAD.html.
Results
Likelihood mapping analysis of the data set
The phylogenetic noise of the data set was investigated by
means of likelihood mapping. The evaluation of 10,000 random
quartets showed that more than 92.7% of the randomly chosen
quartets fell in the corners, and only 2.7% in the central area of the
likelihood map, thus indicating that the alignment contained
sufficient phylogenetic information (Figure S1).
Estimated evolution rates
The mean evolutionary rate of the HBV-D P sequences was
evaluated on a data-set including 216 isolates with known
sampling dates.
Comparison of the strict and relaxed clock models using the BF
test showed that the relaxed clock fitted the data significantly
better than the strict clock (2lnBF= 316.4 in favour of the relaxed
clock). Comparison of the coalescent priors showed that the BSP
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model was better than the constant (2lnBF=222.27) or exponen-
tial growth model (2lnBF= 140.9).
Under the relaxed clock model, the estimated mean value of the
990-nt fragment of the P gene was 4.461024 subs/site/year
(95%HPD 2.661024–6.261024), and this external rate estimate
was used for the subsequent analyses.
Phylogeographical analysis
Figure 1 shows the maximum credibility tree of the main data
set, using the previously estimated mean evolutionary rate of the
HBV P sequences as a prior probability distribution. The figure
shows the most probable location of each branch in different
colours, and the tMRCA estimates under relaxed molecular clock.
Analysis of the tree showed that the 312 HBV genotype D isolates
segregated into a number of significant clades corresponding to the
main subgenotypes D present in the geographic area considered
(D1, D2, D3, D5 and D7). In particular, HBV D5 and D7 formed
two highly significant clades (pp= 1 each one) that diverged from
the tree root earlier than the other subgenotypes. The isolates
belonging to the three major subgenotypes (D1–D3) formed three
clades (with pp values of respectively 0.73 and 1) sharing two
highly significant ancestors: the first common to all three
subgenotypes (pp= 0.89) and the second shared only by D1 and
D2 (pp= 0.88).
Phylogeographical analysis showed that India had the highest
posterior probability to be the location of the tree root (pp= 0.30),
significantly higher than that of the second most probable location,
the Central Asia (pp= 0.22) (see histogram in Figure 1 for more
details), which was the most probable location of the deepest nodes
of the tree: i.e. the common ancestors of D1–D3 and D1–D2 (pp
values of respectively 0.33 and 0.43).
Two clades included isolates from homogenous geographical
areas: clade D5 encompassed only Indian isolates, and D7 isolates
from Tunisia (Table 1). As all of the other clades included isolates
from different parts of the world, we analysed each subgenotype
separately.
The strains in clade D1 were isolated in India, Central Asia
(Kazakhstan and Uzbekistan), the Far East (China and Vietnam),
Tunisia, Iran, Egypt, north-eastern Europe, and Italy, and formed
only small groups of no more than five isolates. Turkey had the
greatest posterior probability (pp= 0.40) of being the location of
the D1 MRCA, followed by Central Asia (pp= 0.30) and Iran
(pp= 0.22) (Figure S2A). There was no significant geographical
structure.
The clade corresponding to the D2 subgenotype (Figure S2B)
included a large prevalence of isolates from Russia, Belarus and
Figure 1. The maximum clade credibility (MCC) tree of HBV-D P gene sequences. The branches are coloured on the basis of the most
probable location state of the descendent nodes (see colour codes in upper left inset). The numbers on the internal nodes represent posterior
probabilities, and the scale at the bottom of the tree represents the years before the last sampling time (2007). The clades corresponding to the main
HBV-D subgenotypes (D1, D2, D3, D5, D7) are highlighted.
doi:10.1371/journal.pone.0037198.g001
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Estonia, a large group of Albanian isolates, a number of Italian
strains, and sporadic isolates from Greece and Turkey. Central
Asia and Russia (state pp= 0.33 and 0.30 respectively) shared the
vast majority of posterior distribution with a 0.63 cumulative
probability of being the location of the MRCA (followed by
Albania: pp= 0.22). All of the D2 isolates tended to segregate
significantly on the basis of their geographical origin. In particular,
there were two highly significant sub-clades: sub-clade D2a
(pp= 0.99) included all of the Albanian and several Italian strains,
indicating Albania as the most probable MRCA location
(pp= 0.96); the D2b sub-clade (pp= 0.81), which included all of
the north-east European and a few Italian strains, had Russia as its
most probable MRCA location (pp= 0.96).
The D3 clade included a number of Italian isolates, several
Albanian and north-east European strains, three isolates from
Serbia, four from India and one from Mongolia; a group of six
South African isolates significantly segregated from the other
strains. One single Indian isolate (Ne20D3) was at the outgroup
(Figure S2C). Central Asia and India shared the highest posterior
probability of being the location of the D3 MRCA (cumulative
pp= 0.54, 0.27 for both). All of the D3 isolates tended to segregate
significantly on the basis of their geographical origin.
Using a BF test under BSSVS, we identified the main linkages
between the different locations. Figure 2 (see Table S1 for more
details) shows all of the rates with a non-zero expectancy and a BF
of $6. Interestingly, among the most significant rates, India linked
only with central Asia (BF=27.3), whereas central Asia was
related to five locations (Russia, the Far East, Turkey, Iran and
India), thus suggesting it played a central role in the global
dispersion of HBV-D. Other locations with several significant
linkages were Russia (with Italy, Spain, and central Asia) and
Turkey (with central Asia, Iran and Egypt/Israel), and Italy (with
Russia, Albania and South Africa).
Estimated times of the most recent common ancestors
(tMRCA)
Using the relaxed molecular clock model described in Methods,
we estimated the tMRCA of all of the internal nodes of the
Bayesian tree. In particular, the estimated mean tMRCA of the
tree root was 128 years ago (95%HPD 66–210 years), thus
suggesting that the origin of the D subgenotypes goes back to 1880
(credibility interval 1798–1942). HBV-D5 and D7 were the first
subgenotypes to diverge from the root, although their radiation is
relatively recent (40 and 52 years ago, corresponding to 1968 and
1956; see Table 1). On the basis of our estimates, the ancestor
shared by D1–D3 existed a mean 86 years ago (about 1922) and
that shared by D1 and D2 68 years ago (1940). Once again, the
time of subgenotype radiation was more recent: 65 years ago
(95%HPD 37–101) for HBV-D3 (1943), and 52 years ago (1956)
for D2 and 48 years ago (1960) for D1. On the basis of the
tMRCA estimates, the two D2 sub-clades (A and B) originated in
1963 (95%HPD 1943–1981) and 1965 (95%HPD 1945–1981)
respectively.
Discussion
HBV genotype D is found throughout the world: it is the most
prevalent genotype in north-eastern Europe, the Mediterranean
basin, northern Africa, and the Middle East; it is highly prevalent
in the Indian sub-continent and a group of island in the Indian
Ocean with high endemic levels of HBV (Nicobare and Andaman)
[33]; and it has also been identified in Oceania [20].
It is characterised by a high degree of heterogeneity. Using
a relaxed molecular clock model, we estimated the evolutionary
rates of the P sequences in a sub-set of dated isolates as ranging
from 2.6 to 6.261024 subs/site/year. Previous studies have
suggested evolutionary rates varying between 1.561025 and
7.7261024 subs/site/year [34–39]. Recently, we showed that
the average substitution rate of genotype D was higher than that of
the other genotypes (particularly genotype A) and suggested that
these differences were mainly due to population-related factors
such as the wider spread of the HBV-D epidemic and the different
main routes of transmission of the two genotypes [22]. In the last
year, Harrison et al. [40] have reported slower viral evolutionary
rates during hepatitis B e antigen positive state, compared to
hepatitis B e antigen negative state. It is well known that HBV
genotypes influence the HBeAg state, as a number of mutations
that reduce HBeAg expression (such as those affecting nucleotide
1896 of the Pre-core region) occur more frequently in genotype D,
Table 1. tMRCAs and locations of the main clades.
Node tMRCA1 95%HPD U2 95%HPD L3 Years Credibility intervals MRCA states pp4
Root 128 66 210 1880 1798–1942 India 0.3
D1–D3 86 47 135 1922 1873–1961 Central Asia 0.33
D1–D2 68 37 104 1940 1904–1971 Central Asia 0.43
D1 48 27 70 1960 1938–1981 Turkey 0.40
D2 52 31 78 1956 1930–1977 Central Asia+Russia 0.63
D2A 45 27 65 1963 1943–1981 Albania 0.96
D2B 43 27 63 1965 1945–1981 Russia 0.96
D3 65 37 102 1943 1906–1971 Central Asia+India 0.56
D5 40 22 62 1968 1946–1986 India 0.95
D7 52 30 80 1956 1928–1978 Tunisia 0.99
1tMRCA: Time of the most recent common ancestor.
295%HPD U 95%: Highest Posterior Density Upper.
395%HPD U 95%: Highest Posterior Density Lower.
4pp: posterior probability.
Time of the most recent common ancestor (tMRCA) estimates with credibility intervals (95%HPD) with corresponding years and most probable locations with state
posterior probabilities (pp) of the main clades observed in the MCC tree of Figure 2.
doi:10.1371/journal.pone.0037198.t001
Phylogeography of Hepatitis B Virus D Genotype
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37198
than among others [41]. This may further explain the higher
evolutionary rates of HBV-D.
On the basis of the evolutionary rate estimate obtained, we
inferred the tMRCA of every internal node within the Bayesian
tree of the entire data set. Interestingly, our time-scaled re-
construction supported a relatively recent history of the currently
circulating HBV-D genotype with the time of the tree root being
128 years ago, in line with previous estimates [22,39]. This
estimate suggests that the common ancestor of the D genotype
existed in the second half of the XIX century.
The origin of D genotype and subgenotypes and their spread
throughout the world is still obscure. Ours is the first attempt to
reconstruct the epidemiological history of HBV-D genotype
phylodynamically and phylogeographically. Our reconstruction
shows that the most probable location of the tree root is India,
which suggests that the Indian sub-continent was the place in
which HBV-D originated. This is supported by the fact that
genotype D is highly prevalent in India, which hosts at least four
HBV-D subgenotypes with very different local distributions: D1 is
the most prevalent in northern India, D2 in western India, D3 is as
prevalent as D2 in eastern India [42], and the recently reported
D5 (the only subgenotype present in a primitive tribe in South-
East India) [19]. As shown by our analysis and previous reports
[43], D5 was probably the first subgenotype to diverge from the
root of the phylogenetic tree.
As we were interested in studying the HBV-D subgenotypes
mainly circulating in Europe and the Mediterranean area, no D4
isolates were included in our analysis. One recent study has
confirmed that D5 was the first subgenotype emerging from the
tree [43], and found that D4 formed a significant group with D7,
a finding that is supported by a preliminary review of our own data
which include a few D4 sequences (Figure S3). These observations
and the very high degree of HBV-D genetic divergence suggest
that India was the cradle of the HBV-D genotype.
HBV D1–D3 share more recent ancestors which, on the basis of
our phylogeographical reconstruction, were most probably located
in Central Asia. Our tMRCA estimate suggests that the D1–D3
MRCA existed in the first decades of the XX century (1922), with
D3 being the first subgenotype to diverge in the early 1943 while
the radiation of subgenotypes D1 and D2 probably occurred
between the mid- 1950s and early 60s. Only a few data are
available concerning HBV genotype prevalence in central Asia.
HBV-D is the most prevalent genotype in Uzbekistan, Tajikistan
and Kazakhstan [44–46], and one of these studies [11] found that
D1 was the most prevalent subgenotype. Much more data support
the greater prevalence of D1 than the other subgenotypes in Iran
Figure 2. Significant non-zero HBV-D migration rates worldwide. Only the rates supported by a BF of .6 are shown. The relative strength of
the support is indicated by the colour of the lines (from dark red=weak to light red= strong). The map was reconstructed using SPREAD (see
Methods).
doi:10.1371/journal.pone.0037198.g002
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[10,47], Turkey [8], Pakistan [48,49] and Afghanistan [50]. In line
with these data, Turkey had the highest posterior probability of
being the location of origin of D1, followed by Central Asia and/
or Iran. The lack of any significant geographical segregation of D1
strains suggests the relatively recent penetration of HBV-D1 in this
area as a result of multiple introduction events, probably due to
frequent exchanges with neighbouring countries.
HBV D2 (the most prevalent subgenotype in north-eastern
Europe) has two distinct clades, one originating in Russia and the
other in Albania [11,12,46,51,52]. In our reconstruction, the D2
clade as a whole probably originated somewhere between central
Asia and Russia as they had similar posterior probabilities.
The phylogeography of the D3 subgenotype remains elusive
although, once again, central Asia and India seem to be the most
likely locations of origin. The reason for this uncertainty was the
scarcity of dated HBV D3 sequences collected in places other than
Italy, which represented the majority of the available strains. It has
been shown that subgenotype D3 (and particular strains carrying
specific mutations such as the T125M in the a determinant) is
prevalent among IVDUs in various countries, including Italy,
Denmark, the USA, British Columbia, Belgium and Serbia
[13,20,53–56]. These observations, partially strengthened by the
high prevalence of this subgenotype in India or Pakistan [49],
suggest that the international drug trade may have played a role in
its spread, at least in recent times. Our recent study suggested the
presence of D3 in Italy even before the epidemic of intravenous
drug addiction in the early 1970s, rising questions about other
possible routes of geographic dispersion of this strain [22].
Nevertheless our analysis suggests that D3 was the earlier
subgenotype diverging in 1940s.
Combining our temporal and spatial reconstructions of the
evolutionary dynamics of HBV-D, our data suggest that, by the
end of the XIX century, its ancestor left India and reached central
Asia, where subgenotypes D1–D3 diverged. Central Asia was the
source of their further spread to Europe and the Mediterranean
area in the first decades of the XX century by means of at least two
routes: a south-western route (mainly due to the diffusion of
subgenotype D1) crossing the Middle East (where most probably
D1 diverged) and reaching north Africa and the south-eastern
Mediterranean, and a second route (closely associated with D2)
towards the north-west, which crossed the former Soviet Union
and reached eastern Europe and the Mediterranean through
Albania [12]. A third possible epidemic of HBV in Eurasia is
represented by the diffusion of D3, which still remains obscure.
The spread of the main European HBV subgenotypes dates to
a period of time including the First and especially the Second
World War. The importance of war in the history of hepatitis
viruses has been efficiently explained by Reuben [57]. Times of
war provide many opportunities for infection, such as massive
vaccines administration to soldiers, wounds, blood transfusions
and other violence-related factors. The largest recorded outbreak
of viral hepatitis occurred in 1942, when more than 28,000 US
soldiers developed jaundice (and 62 died) after being inoculated by
an HBV-contaminated yellow fever vaccine [58,59]. Subsequent
studies of veterans have shown that 97% of the subjects who
received this vaccine were positive for serum markers of HBV
infection [60]. We can hypothesise that this or similar events, such
as the outbreaks of jaundice following the intravenous injection of
arsphenamine (the main anti-syphilis treatment from the early
1920s to the late 1940s) led to the spread of some HBV D
subgenotypes in Europe [61,62]. The spread of D genotype could
have been subsequently amplified locally by other routes.
In particular, the rate of vertical transmission is relatively low in
populations in which genotype D is predominant probably
because of the high rate of mutations causing HBeAg negativity
in this genotype. Consequently, the majority of infections are
acquired horizontally within these populations [63], mainly as
a result of the use of unsterilised needles and syringes, and
household contacts [64,65]. In line with our spatio-temporal
reconstruction of HBV-D epidemics, the unsafe use of injections in
medical practice was still a problem in India and the Middle East
in the year 2000, when about 70% of the equipment was reused
[66], and about 57% of HBV infections in India were attributable
to this route of transmission [67,68]. Unsafe injections have also
been indicated as a possible cause of the spread of HBV in east
European countries such as Moldavia [69] and Romania [70].
One further event that probably contributed to the rapid
diffusion of HBV-D is the intravenous drug use epidemic that has
affected Europe since the early 1970s. A recent literature review
has pointed out that the greatest prevalence of HBsAg among
IVDU populations is in the eastern Mediterranean and eastern
Europe [71], where the most prevalent genotype is HBV-D.
In conclusion, HBV-D is highly prevalent in eastern and
southern Europe, where HBV is highly endemic and the main
transmission route is unsafe injections. On the contrary, genotype
A is highly prevalent in central and northern Europe, where HBV
is mainly sustained by sexual transmission [4,65,72]. This
observation recalls the epidemiological dichotomy previously
described by us in Italy [22], and suggests that similar
population-related mechanisms may have played a role in the
different distribution and evolutionary dynamics of the two main
HBV genotypes throughout Europe.
Supporting Information
Figure S1 Likelihood map of the 312 HBV-D P gene
sequences. Each dot represents the likelihoods of the three
possible unrooted trees per quartet randomly selected from the
data set: the dots near the corners or sides respectively represent
tree-like (fully resolved phylogenies in which one tree is clearly
better than the others) or network-like phylogenetic signals (three
regions in which it is not possible to decide between two
topologies). The central area of the map represents a star-like
signal (the region in which the star tree is optimal tree). The
numbers indicate the percentage of dots in the centre of the
triangle.
(TIF)
Figure S2 Part of the MCC tree shown in Figure 1
focusing on the D1 (a), D2 (b) and D3 (c) clades. The
branches are coloured on the basis of the most probable location
state of the descendent nodes (see colour codes in upper left inset).
The numbers on the internal nodes represent posterior probabil-
ities, and the scale at the bottom of the tree represents the years
before the last sampling time (2007). Subclades D2a and D2b are
highlighted (panel b).
(TIF)
Figure S3 The maximum clade credibility (MCC) tree,
including also three D4 isolates. The branches are coloured
on the basis of the most probable location state of the descendent
nodes (see colour codes in upper left inset). The numbers on the
internal nodes represent posterior probabilities, and the scale at
the bottom of the tree represents the years before the last sampling
time (2007).
(TIF)
Table S1 Significant migration rates.
(DOC)
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